Johnson & Johnson’s drug Balversa won U.S. approval as the first targeted therapy for advanced bladder cancer, the Food and Drug Administration announced.
Nektar Therapeutics said some patients with advanced bladder cancer treated with a combination of the company’s experimental treatment and Bristol-Myers Squibb’s immunotherapy Opdivo showed signs of tumor reduction in an early-stage study.
Roche Holding AG’s Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.
Swiss group Roche Holding AG said the company’s Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals’ revenues.
The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.
The first comprehensive study comparing the outcomes of robotic surgery to those of traditional open surgery in any organ found that the surgeries are equally effective in treating bladder cancer.
UroGen Pharma plans to begin a mid-stage trial of the company’s treatment for bladder cancer patients after positive interim results from an advanced trial of a treatment for upper urinary tract cancer.
The European Medicines Agency recommended restricting use of two immunotherapies – one from Roche and the other from Merck – in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.
Shares of newly dubbed Sesen Bio plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer trial.